Psoriasis · biologics — v1.0
Fictional tenant Halcyon Therapeutics. Pilot asset Velcarib. Watermark SYNTHETIC-APIARY on every row.
Datasheet
| Status | golden |
|---|---|
| Quality / realism | 100 / 100 |
| Seed | 20260311 |
| Patients / HCPs / drugs | 12000 / 1500 / 69 |
| METex14 cohort | 960 |
| Rows added this version | 1846 |
| Checksum | b020670c3fdd4efc09… |
Lineage
Sources with rows
| ID | Source | Class | Rows |
|---|---|---|---|
| INT-01 | CRM, medical instance (spec: Veeva CRM Medical, Salesforce Health Cloud) | internal | 360 |
| INT-02 | HCP and HCO master (OneKey, client MDM) | internal | 48 |
| INT-03 | Medical Information system (Vault MedInquiry, IRMS, Salesforce MI) | internal | 48 |
| INT-04 | Content and MLR (Vault PromoMats or MedComms) | internal | 48 |
| INT-05 | Publication planner (Datavision, PubSTRAT, iEnvision) | internal | 48 |
| INT-06 | Congress planning tracker | internal | 48 |
| INT-07 | CTMS and trial data mart (Vault CTMS, Medidata, Oracle) | internal | 48 |
| INT-08 | Safety database visibility (Argus, ArisG, Vault Safety), aggregate only | internal | 48 |
| INT-09 | Transparency system (Open Payments filing, EFPIA disclosure) | internal | 48 |
| INT-10 | Advisory board management | internal | 48 |
| INT-20 | Evidence register (Planisware, Vault, Smartsheet, spreadsheet) | internal | 48 |
| INT-21 | Claims library | internal | 48 |
| INT-22 | Integrated evidence plans and dossiers | internal | 48 |
| INT-23 | Finance ERP (SAP, Oracle) | internal | 48 |
| INT-25 | Grants and IIS portal | internal | 48 |
| INT-26 | Local affiliate intake | internal | 48 |
101 catalog sources on this release, including referenced public sources and vocabularies with zero shipped rows.
Realism
female_pct=52.1; age_median=50; biologic_pct=66.3; us_pct=62.5; lot1_pct=64.4; msl_anchored_pct=100
Messiness log
Public context the scout cached
Sample MSL notes
DE · Lumenra · Elderly patients (>=75)
Synthetic Lumenra note on plaque psoriasis and line of therapy. No real person is described.
GB · Lumenra · Payer access barriers
Synthetic Lumenra note on plaque psoriasis and line of therapy. No real person is described.
FR · Lumenra · Elderly patients (>=75)
Synthetic Lumenra note on plaque psoriasis and line of therapy. No real person is described.
JP · Lumenra · Elderly patients (>=75)
Synthetic Lumenra note on plaque psoriasis and line of therapy. No real person is described.